Lauren Marangell
Psychiatry · Houston, TXNPI 1861699704
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $54,815 of the $81,371 with a category attached, or 67.4%. 13 manufacturers reported payments, led by UCB SA at 48.7% of the total. Reporting peaked in 2019 at $27,556 and has fallen 72.4% since, to $7,600 in 2025. Among psychiatry clinicians in TX with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 157 payments — averaging $518.29 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- UCB SA$40K
- Johnson & Johnson$38K
- E.r. Squibb & Sons, L.L.C.$3K
- AbbVie$147
- Takeda Pharmaceuticals U.S.A., Inc.$138
- Omniscient Neurotechnology America Ltd$123
- plus $368 from 7 others
Across 1 payment — averaging $500.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- E.r. Squibb & Sons, L.L.C.$500
What the payments were for
- Consulting fees$54,81567%
- Speaking & faculty fees$19,54524%
- Travel & lodging$4,1405%
- Food & beverage$2,7993%
- Education$720%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| UCB SA | 23 | $39,625 |
| Johnson & Johnson | 97 | $37,870 |
| E.r. Squibb & Sons, L.L.C. | 2 | $3,100 |
| AbbVie | 7 | $147 |
| Takeda Pharmaceuticals U.S.A., Inc. | 8 | $138 |
| Omniscient Neurotechnology America Ltd | 2 | $123 |
| Otsuka America Pharmaceutical, Inc. | 4 | $90 |
| Shire North American Group Inc | 4 | $89 |
| Bausch Health US, LLC | 4 | $81 |
| Sunovion Pharmaceuticals Inc. | 2 | $38 |
| OWP Pharmaceuticals, Inc. | 1 | $28 |
| Neuronetics, Inc. | 2 | $23 |
| Lundbeck LLC | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$81,371 in reported general payments places this provider in the 95th percentile of 2,238 psychiatry providers in Texas.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Clozapine | 21 | $4,131 |
| Aripiprazole | 34 | $1,543 |
| Duloxetine Hcl | 91 | $1,114 |
| Escitalopram Oxalate | 28 | $487 |
| Mirtazapine | 52 | $404 |
| Clonazepam | 88 | $357 |
| Gabapentin | 23 | $327 |
| Lamotrigine | 19 | $241 |
| Quetiapine Fumarate | 22 | $241 |
| Ziprasidone Hcl | 14 | $220 |
| Eszopiclone | 11 | $208 |
| Bupropion XlBupropion Hcl | 15 | $166 |
| Fluoxetine Hcl | 19 | $161 |
| Lithium Carbonate | 16 | $129 |
| Desvenlafaxine Succinate ErDesvenlafaxine Succinate | 12 | $117 |
Paid to pharmacies, not to this prescriber.
Other psychiatry in Houston
- Matthew BramsHouston$1.5M
- Frank ChenHouston$941K
- Alice MaoHouston$850K
- Mazhar KhowajaHouston$843K
- Barry GritzHouston$792K
- Aaron PetersonHouston$700K
- Ayesha RashidHouston$641K
- Lawrence GinsbergHouston$502K
- Kathy FlanaganHouston$443K
- Rayan Al JurdiHouston$359K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.